Key Highlights

  • BLLN shares traded up 3.71% intraday to $94.03, extending gains from a $90.67 prior close.
  • Northstar Origin predicts tissue of origin directly from a single blood draw, addressing cancer of unknown primary cases.
  • In a validation study of 1,578 patients, the test identified the correct tissue of origin as its top prediction in 87% of cases.
  • The company also expanded its Northstar Select genomic profiling panel from 84 to 102 genes.

Northstar Origin Targets a Persistent Diagnostic Challenge

BillionToOne (NASDAQ:BLLN) shares traded higher after the company announced the launch of Northstar Origin, a new liquid biopsy add-on test that predicts tissue of origin directly from circulating cell-free DNA for patients with cancer of unknown primary or uncertain cancer diagnoses. The test is ordered alongside Northstar Select and does not require additional tissue or a separate blood draw.

BillionToOne is a next-generation molecular diagnostics company focused on creating accurate tests that are accessible to all patients. The company's Quantitative Counting Templates platform is a proprietary molecular counting technology capable of detecting DNA molecules at the single-molecule level.

Validation Data Shows Strong Diagnostic Accuracy

Northstar Origin's performance was evaluated in an independent validation cohort of 1,578 patients, after the supervised classifier was developed using more than 6,000 blood samples from advanced cancer patients. In this evaluation, the model identified the correct tissue of origin as its top prediction in 87% of cases, and within its top three predictions in 91% of cases. BillionToOne carries a market Capitalization of roughly $4.32 billion.

Expanded Genomic Panel Adds to the Announcement

Alongside the Northstar Origin launch, BillionToOne also announced the expansion of its Northstar Select comprehensive genomic profiling panel from 84 to 102 genes, adding coverage for biomarkers included in recent and upcoming regulatory approvals. The expanded panel maintains the assay's sensitivity while broadening the range of clinically actionable mutations it can detect.

Broader Liquid Biopsy Momentum Supports the Move

The product news comes amid a broader wave of positive catalysts across the liquid biopsy and molecular diagnostics sector, with peers reporting new clinical guideline inclusions and updated data disclosures in recent weeks. That sector-wide momentum has added some tailwind to the stock's reaction to today's announcement.

Prospective Studies Will Be the Next Milestone to Watch

BillionToOne has indicated it plans prospective studies to expand the Northstar Origin model to additional tumor types and further evaluate its clinical utility. Investors will watch for updates on that research program as the next signal of the test's broader commercial potential.